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Preventing Sudden Death: Implantable Cardioverter-Defibrillators in Elderly
Cardiac Patients
Abstract
Much of the public was introduced to the implantable cardioverterdefibrillator (ICD) when Vice President
Cheney, a survivor of four heart attacks, received the device in 2001. Although ICDs were initially limited to
patients with previous cardiac arrests or arrhythmias, more recent studies have demonstrated that ICDs
can prevent sudden cardiac death in patients who have not had a cardiac arrest, but are at greater risk for
one (for example, those with congestive heart failure and reduced cardiac function). This Issue Brief
summarizes studies that analyze health outcomes, costs, and quality of life for patients-at-risk who
receive ICDs in real-life settings.
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The ICD is one of the
most common
cardiovascular devices
in use

An ICD is a small device implanted in a patient’s chest to monitor the heart’s
rhythm and deliver an electrical shock if a life-threatening arrhythmia occurs. More
than 100,000 ICDs were implanted in 2005, making them among the most
common cardiovascular devices in use. In general, patients receive an ICD for one
of two reasons: to prevent sudden cardiac death in patients with a history of cardiac
arrest or irregular heart beat (secondary prevention) and to prevent the initial cardiac
arrest in patients at greater risk due to congestive heart failure (CHF) or related
conditions (primary prevention).

Editor’s Note: Much of the public was introduced to the implantable cardioverterdefibrillator (ICD) when Vice President Cheney, a survivor of four heart attacks,
received the device in 2001. Although ICDs were initially limited to patients with
previous cardiac arrests or arrhythmias, more recent studies have demonstrated that
ICDs can prevent sudden cardiac death in patients who have not had a cardiac
arrest, but are at greater risk for one (for example, those with congestive heart failure
and reduced cardiac function). This Issue Brief summarizes studies that analyze
health outcomes, costs, and quality of life for patients-at-risk who receive ICDs in
real-life settings.

• Patients receiving ICDs for primary prevention are the fastest growing segment of
the ICD recipient population. It is estimated that hundreds of thousands of
patients with CHF and poor ventricular function, many over age 65, are now
potential candidates for ICDs.
• Based on clinical studies, Medicare and other health care payers issued policy
decisions in 2003 and 2005 extending coverage of ICDs to patients for primary
prevention. In 2005, more than 40,000 Medicare beneficiaries received ICDs.
• Although clinical trials have shown that primary prevention ICDs are costeffective, the costs and outcomes of ICDs when used in routine clinical practice in
CHF patients is not known. Also little is known about the impact of ICDs on
primary prevention patients’ quality of life.

Continued on next page.

Study assesses ICD
outcomes and costs in the
Medicare population

Groeneveld and colleagues assessed health outcomes and costs among elderly
Medicare beneficiaries hospitalized for CHF and related diagnoses who had received
primary ICDs between October 2003 (when Medicare first expanded ICD coverage)
and September 2005. Study patients included a nationally representative sample of
Medicare patients who were treated at more than 2,000 academic and community
hospitals nationwide.
• The investigators studied 7,125 ICD recipients and compared them with an equal
number of “control” patients with similar diagnoses who did not receive ICDs.
The groups were closely matched across multiple demographic and clinical
variables.
• Patients with advanced, end-stage heart failure were excluded from the study,
because ICDs would have been clinically inappropriate.
• Medicare databases were used to compare outcomes between the two groups
through December 2005, including length of hospital stay, rehospitalizations,
complications, and mortality.
• Inpatient and outpatient claims data were used to calculate and compare the
incremental costs of the ICD in this elderly cohort.

Primary prevention
patients with ICDs live
longer, with higher
upfront medical costs

The study found that ICD patients, after adjusting for small residual differences in
demographic and clinical factors, had a 38% lower mortality rate than patients who
did not receive an ICD.
• Short-term mortality differed markedly between the two groups: 13% of ICD
recipients died in the first year after implantation, compared to 23% of the
matched controls. This difference widened in the second year, with 17% of ICD
recipients and 29% of controls dying within 24 months of the initial
hospitalization.
• During their initial hospitalization, ICD patients were more likely to have critical
care stays of more than 3 days, and hospital stays of more than 6 days. About
14.5% of ICD patients developed complications during the first 30 days after
hospitalization, compared to about 1.5% of controls.
• ICD patients had higher median hospital costs in the first 30 days after initial
hospitalization (median difference = $41,542) and at 1 year (median difference =
$41,503) as well as higher outpatient and physician costs at 6 months (median
difference = $1,828).
• Although the study did not have sufficient follow-up to fully estimate costeffectiveness, the upfront cost difference and survival benefit is consistent with the
findings of previous ICD cost-effectiveness analyses. One well-known study
found that the cost-effectiveness of ICDs was $38,389 per life-year saved, well
within the U.S. standards for cost-effective preventive care.

Study compares the
health-related QOL
among primary and
secondary prevention ICD
patients

It is uncertain how the ICD affects the quality of life (QOL) experienced by primary
prevention patients. Previous studies of QOL had been conducted among secondary
prevention patients (who had already suffered cardiac arrest or arrhythmias). Those
studies found that ICDs improved patients’ QOL by enhancing security, but
negatively affected QOL due to the unpredictability of the shocks. Groeneveld and
colleagues measured and compared QOL in both primary and secondary prevention
ICD recipients.
• In 2006, the investigators surveyed 45 primary prevention and 75 secondary
prevention ICD patients receiving electrophysiological care at the University of
Pennsylvania and reviewed medical records to determine the reason for the ICD
implantation, the date of implantation, and ICD shock history.
• Each patient completed several QOL instruments to assess both overall healthrelated QOL and ICD-specific QOL.
• As the use of ICDs for primary prevention is a more recent phenomenon, patients
receiving an ICD for secondary prevention reported a much greater duration of
time living with their devices compared to primary prevention patients (median
of 3 years vs. 1 year).

Both primary and
secondary prevention
patients had overall QOL
scores virtually identical
to similarly aged adults in
the general population

The study found remarkably few QOL differences between primary and secondary
prevention ICD patients and between these patients and similarly aged adults in the
general population.
• Although the ICD was highly acceptable to most patients, substantial fractions of
both primary and secondary prevention patients had concerns about lifting
children or heavy objects (40%), sexual activity (19%), and driving (14%).
• Secondary prevention patients were more likely to report having received a shock
from their devices (51% versus 11%). ICD shocks were associated with higher
QOL in secondary prevention patients but associated with lower QOL in primary
prevention patients. It may be that secondary prevention patients assessed their
risk of sudden cardiac death as being higher and thus considered their ICD shocks
to be comforting because they were potentially life-saving.

POLICY IMPLICATIONS

These findings confirm, through real-world experience among thousands of patients,
the value of ICDs in the primary prevention of sudden cardiac death. The studies
indicate that ICDs save lives, do so at a reasonable cost, and preserve quality of life.
• ICD costs to both hospitals and patients remain substantial. Further
improvement in the cost-effectiveness of ICDs may come from incentives to
encourage adherence to clinical guidelines in selecting candidates for ICDs. The
American College of Cardiology, American Heart Association, and Heart Rhythm
Society revised the guidelines for use of cardiac rhythm devices, including ICDs,
in May 2008.

Continued on back.

POLICY IMPLICATIONS
Continued

• Care may also be improved further by addressing the high complication rate for
ICD implantation (about 1 in 8 patients in the first 30 days). Policies that
encourage patients to seek the highest quality ICD providers, or reimbursement
rates that reward higher quality ICD providers, may reduce complications related
to ICD implantation.
• Because ICD shocks are sources of ongoing patient concern, clinicians should
specifically reinforce messages about living with an ICD, including the impact of
the device on driving, sexuality, and physical exertion. Primary prevention
patients who have received a shock may require more explanation of the event and
reassurance by clinicians than secondary prevention patients.
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